Chiral metal supramolecular compound, pharmaceutical composition and application of chiral metal supramolecular compound in resistance of monkey pox virus
Through the combination of chiral metal supramolecular compound [Fe2L3]4+ and the mRNA G4 structure of monkey pox virus, the problem of neurotoxicity and poor drug properties of existing drugs has been solved, and effective treatment and prevention of monkey pox virus has been achieved. High safety and drug properties.
Patent Information
- Application Number
- CN202411117056.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-15
AI Technical Summary
Existing drugs used to treat or prevent poxvirus have neurotoxic side effects and poor drug properties, and no drugs approved for treating monkeypox have been approved.
Developed an Λ enantiomer of chiral metal supramolecular compound [Fe2L3]4+, which enhances its stability and expression by binding to the mRNA G4 structure of the monkeypox virus 39kDa core protein, promotes immune responses, and reduces viral spread.
It provides a high-safety and good drug properties with strong monkeypox virus selectivity, which can effectively enhance the expression and immune response of monkeypox virus, prevent the spread of the virus, and show a relatively high level in Vero cells. High drug safety.
Smart Images

Figure CN119015291A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicinal chemistry and relates to a chiral metal supramolecular compound, a pharmaceutical composition and application thereof in resisting monkeypox virus. Background Art
[0002] Monkeypox is a zoonotic disease caused by infection with the Monkeypox virus (MPXV). The monkeypox virus belongs to the Poxviridae family and is mainly transmitted from person to person through direct contact with infectious skin, mouth or genitals. It is not clear whether animals can transmit the virus. People can also be infected with monkeypox through contaminated objects. The monkeypox virus is an enveloped linear double-stranded DNA virus with a genome size of nearly 190kbp. The incubation period of monkeypox is usually 5-12 days. The clinical symptoms are fever, body aches, rash and swollen lymph nodes, and may be accompanied by complications such as pneumonia, encephalitis, keratitis and secondary bacterial infection. The lesions start from the oropharynx and spread throughout the body.
[0003] Currently, there are only reports that Tecovirimat (ST-246), a specific drug for smallpox virus, is expected to become a specific drug for the treatment of monkeypox virus, but it has not been confirmed in clinical practice. Although the JYNNEOS vaccine received emergency use authorization from the U.S. Food and Drug Administration in 2022 and became the only monkeypox vaccine approved in Europe and the United States; however, there is no drug approved for the treatment of monkeypox in clinical practice so far.
[0004] In view of the fact that the drugs used to treat or prevent poxvirus in the prior art have neurotoxic side effects during use and have poor drugability, those skilled in the art are eager to develop a method that has higher drug safety, better drugability, and can effectively treat or prevent diseases caused by monkeypox virus infection. Summary of the invention
[0005] The present invention aims to solve the technical problems that drugs used to treat or prevent poxviruses in the prior art have neurotoxic side effects and poor drugability, and provides a chiral metal supramolecular compound, a pharmaceutical composition and their use in preventing monkeypox virus.
[0006] One of the purposes of the present invention is to provide a chiral metal supramolecular compound for use in the preparation of an anti-monkeypox drug, wherein the chiral metal supramolecular compound is [Fe2L3] 4+ The Λ enantiomer of .
[0007] In a preferred embodiment of the present invention, the chiral metal supramolecular compound is composed of two Fe 2+ It combines with three ligands through coordination bonds to form a hexacoordinated right-handed binuclear metal triple-helical cylindrical structure.
[0008] In a preferred embodiment of the present invention, the structural formula of the ligand is:
[0009]
[0010] In a preferred embodiment of the present invention, the chiral metal supramolecular compound binds to the mRNA G4 structure of the A5L gene, and the A5L gene encodes the 39kDa core protein of the monkeypox virus.
[0011] In a preferred embodiment of the present invention, the mRNA nucleotide sequence of the A5L gene is shown as SEQ ID No.1.
[0012] In a preferred embodiment of the present invention, the effective safe concentration of the chiral metal supramolecular compound added into Vero cells is 10.27 μM.
[0013] The second object of the present invention is to provide a pharmaceutical composition, which comprises a chiral metal supramolecular compound and a pharmaceutically acceptable carrier, wherein the chiral metal supramolecular compound is [Fe2L3] 4+ The Λ enantiomer of .
[0014] The third object of the present invention is to provide the use of the above-mentioned pharmaceutical composition in the preparation of anti-monkeypox drugs.
[0015] Beneficial effects of the present invention: The present invention provides a chiral metal supramolecular compound and a pharmaceutical composition containing the compound, wherein the chiral metal supramolecular compound is [Fe2L3] 4+ The Λ enantiomer (MH3-Λ) is composed of two Fe 2+ It combines with three ligands through coordination bonds to form a six-coordinated right-handed binuclear metal triple-helical cylindrical structure.
[0016] Compared with the prior art, the MH3-Λ provided by the present invention has chiral selectivity and strong selectivity for monkeypox virus RNA; on the one hand, the MH3-Λ provided by the present invention can enhance the stability of A5L mRNA, and the binding constant with the MG G4 structure is 1.22×10 6 , indicating that there is a strong interaction between MG and MH3-Λ; on the other hand, the MH3-Λ provided by the present invention can enhance the expression of the 39k Da core protein of the monkeypox virus, and can also enhance the immune response caused by the monkeypox virus, reduce the production of the monkeypox virus, and prevent the further spread of the monkeypox virus to the surrounding area. Compared with other antiviral drugs, the MH3-Λ provided by the present invention has higher drug safety, better drugability and better monkeypox virus selectivity, and can be used to prepare drugs for treating or preventing diseases caused by monkeypox virus infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is the chemical structure and characterization of the chiral metal supramolecular compound in Example 1, A is the structural formula diagram of MH3 ligand, B is the structural schematic diagram of MH3-Λ and MH3-Δ, C is the CD spectrum of Λ and Δ enantiomers of MH3, and the abscissa Wavelength is the wavelength;
[0018] Figure 2 The figure is the result of bioinformatics prediction of G-quadruplex of monkeypox virus genome in Example 2, A is the flow chart of bioinformatics analysis of potential G4 structure of monkeypox virus, B is the preliminary analysis result of GC% and QGRS G4 score, the horizontal axis Monkeypox viral genome is the monkeypox virus genome, C is the G4H score evaluation diagram through PGQs, D is the conservation analysis diagram of 39kDa virion core protein G1 in orthopoxvirus; E is the conservation analysis diagram of 39kDa virion coreprotein G3 in orthopoxvirus, and the vertical axis bits is the occurrence frequency of the corresponding base;
[0019] Figure 3 The following are the characteristic diagrams of the MG G4 structure formation in vitro and in cells in Example 2. A is the migration rate determination diagram, B is the NMM fluorescence result diagram, and C is 1 H NMR spectrum, D is the CD spectrum, the ordinate Ellipicity is the ellipticity, E is the intracellular F-MG and BG4 antibody fluorescence co-localization map, and the ordinate FAM / BG4 foci per cell is the number of co-localized fluorescence spots of FAM and BG4 in each cell;
[0020] Figure 4 The graphs are the results of MH3-Λ enhanced MPXV G4 stability in Example 3, A is the fluorescence dissolution curve detection graph, the ordinate Normalized fluorescence is the normalized correlation fluorescence value, the abscissa Temperature is the temperature, and B is the UV titration detection graph;
[0021] Figure 5 A is a schematic diagram of the EGFP reporter gene plasmid in Example 3; A is a schematic diagram of the MG-WT-EGFP reporter gene plasmid, and B is a schematic diagram of the MG-Mut-EGFP reporter gene plasmid;
[0022] Figure 6The figure is the effect of MH3 on the expression of MG-WT-EGFP reporter gene in Example 3, A is the confocal fluorescence experimental detection figure, B is the Image-J fluorescence quantitative detection figure, the ordinate Relative fluorescence is the relative fluorescence intensity, and C is the Western blotting detection figure;
[0023] Figure 7 The figure is a diagram showing the effect of MH3 on the expression of the MG-Mut-EGFP reporter gene in Example 3, A is a confocal fluorescence experimental detection diagram, and B is an Image-J fluorescence quantitative detection diagram;
[0024] Figure 8 This is a schematic diagram of the A5L-EGFP reporter gene plasmid in Example 3;
[0025] Fig. 9 Figure 3 is the effect of MH3-Λ on the expression of A5L-EGFP reporter gene in Example 3, A is the confocal fluorescence experimental detection diagram, B is the Image-J fluorescence quantitative detection diagram, and C is the Western blotting detection diagram;
[0026] Fig.10 This is a graph showing the effect of MH3-Λ on the stability of EGFP mRNA in transfected A5L-EGFP cells in Example 3;
[0027] Fig.11 The figure is the inhibition curve of MH3-Λ on Vero cell activity in Example 3, where the vertical axis Inhibition is the inhibition rate of the drug on cell viability, and the horizontal axis Concentration is the drug concentration;
[0028] Fig.12 The figure is a diagram showing the inhibitory effect of MH3-Λ on monkeypox virus in Example 3, A is a representative virus plaque after treatment with different concentrations of MH3-Λ (24-well plate), B is a graph showing the inhibition of MH3-Λ on monkeypox virus drawn after quantitative analysis of plaque images by image-J, the ordinate Plaque Inhibitor is the inhibition rate of the drug on virus plaques, C is a graph showing the anti-monkeypox virus effect of MH3-Λ evaluated by qPCR, and the ordinate qPCR Inhibition is the virus inhibition rate detected by the qPCR method;
[0029] Fig.13 This is a graph showing the expression levels of inflammatory factors in MPXV-infected Vero cells by MH3-Λ in Example 3;
[0030] Fig.14 This is a schematic diagram of MH3-Λ regulating the antiviral activity of monkeypox virus core protein through G4 in Example 3. DETAILED DESCRIPTION
[0031] Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content and scope of the present invention to implement and apply the technology of the present invention.
[0032] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific implementation methods and the accompanying drawings of the specification. The experimental methods used in the following examples are conventional methods unless otherwise specified, and the materials, reagents, methods and instruments used are conventional materials, reagents, methods and instruments in the art unless otherwise specified, and can be obtained by those skilled in the art through commercial channels.
[0033] In the following examples, the chiral metal supramolecular compound [Fe2L3] 4+ The Λ enantiomer is referred to as MH3-Λ, and the chiral metal supramolecular compound [Fe2L3] 4+ The Δ enantiomer is abbreviated as MH3-Δ.
[0034] The experimental methods involved in the following examples are as follows:
[0035] (1) RNA extraction and cDNA conversion: Total RNA was extracted from cultured cells using a total RNA extraction kit (CWBIO, Beijing, China), and then purified using PrimeScript TM The resulting DNA was converted into cDNA using RT Master Mix (TaKaRa, Japan).
[0036] (2) Quantitative RT-PCR detection: Quantitative RT-PCR detection was performed using SYBR Mix (Beyotime, China) in ABI 7500 (Invitrogen, USA), and the relative expression level of RNA was calculated using the comparative Ct method.
[0037] Reaction system: cDNA 2 μL, 2×SYBR Green qPCR Mix 5 μL, 10 μM upstream and downstream primers 0.5 μL each and RNase Free ddH2O 2 μL; the reaction procedure is shown in Table 1.
[0038] Table 1
[0039]
[0040] (3) Immunoblotting analysis: For protein analysis of whole-cell lysate, cells were lysed with RIPA buffer (CWBIO, Beijing, China), and the lysate was produced on ice for 20 min. The lysate was centrifuged at 4°C, 13,000 rpm for 15 min, and the protein-containing supernatant was transferred to a fresh microcentrifuge tube and stored at -20°C (short-term storage) for the next step. The protein was quantitatively analyzed by BCA protein assay (Beyotime, China). The total protein was electrophoresed on SDS-polyacrylamide gel and the above proteins were transferred to a polyvinylidene fluoride (PVDF) membrane. After incubation with β-actin primary antibody (Bioss, China) on a shaker at 4°C overnight, the membrane was washed three times (8 min each time) with TBST (Invitrogen, USA), and the blot was incubated with horseradish peroxidase-labeled goat anti-rabbit IgG. H&L (Bioss, China) was incubated on a flat shaker at RT for 60 min, and the membrane was washed with TBST (3×10 min). The immunoreactive bands were detected using a chemiluminescent substrate kit (Beyotime, China) and a Western blotting detection system (BioRad, USA), and β-actin was used as a loading control for western blotting detection.
[0041] Example 1: Chiral metal supramolecular compound [Fe2L3] 4+ Preparation of enantiomers
[0042] Step 1: Under nitrogen atmosphere, (R)-2-phenylglycine (0.67 g, 6.0 mmol, 2.2 equivalents) was dissolved in 50 ml of anhydrous tetrahydrofuran, and 0.6 ml (0.67 g, 3.0 mmol, 1.3 equivalents) of 15-crown ether-5 was added by injection; then the above solution was added dropwise to pure sodium hydride (0.4 g, 10.0 mmol, 4.4 equivalents) to obtain a foamy mixture; the above foamy mixture was placed under static vacuum and stirred at room temperature for 1 h, and then 2,8-bis(bromomethyl)dibenzofuran (0.8 g, 2.3 mmol, 1 equivalent) was added dropwise in anhydrous tetrahydrofuran (40 ml) l) solution, stirring the reaction under static vacuum conditions to obtain a mixture; treating the above mixture at room temperature for 1 hour, and then treating it at 65°C for 5 hours, cooling the obtained dark green-gray reaction mixture, and then quenching it with 2:1 saturated KCl aqueous solution / water (60 ml), extracting the crude product with diethyl ether (3×100 ml), drying it over sodium sulfate, filtering it through diatomaceous earth, and removing the solvent under low pressure to leave a yellow oil as the crude product; purifying the above obtained crude product by distillation through a Kjeldahl distillation head (150°C, 45 min) to remove unreacted excess phenylglycinol, and finally obtaining an optically pure diamine.
[0043] Step 2: Dissolve 7.5 mg / mL of the optically pure diamine (3.0 equivalents) and 15 mg / mL of 2-pyridinecarboxaldehyde (6.0 equivalents) obtained in step 1 in methanol (50 ml), stir at room temperature for 2 h to obtain a yellow solution containing the ligand, then add 5 mg / mL of anhydrous iron (II) chloride (2.0 equivalents) to the above solution, and stop adding anhydrous iron (II) chloride (2.0 equivalents) when the color is observed to immediately turn into dark purple, then reflux the above solution at 80°C for 48 h, filter through groove filter paper, remove the solvent under low pressure to obtain a dark purple solid product, and dry the above product under vacuum at 50°C overnight to obtain a chiral metal supramolecular compound [Fe2L3] 4+ The Λ enantiomer of MH3-Λ; and the chiral metal supramolecular compound [Fe2L3] 4+ The Δ enantiomer of MH3 is abbreviated as MH3-Δ.
[0044] The chiral metal supramolecular compound [Fe2L3] prepared in this example 4+ The structure of the ligand described in Figure 1 A shows, respectively, Λ enantiomer and Δ enantiomer; the structure of the metal helical compound of its enantiomer is as follows Figure 1 B shows the CD spectrum of its enantiomer. Figure 1 As shown in C.
[0045] Example 2: Determination of G4 structure in the MPXV genome
[0046] In this example, the National Center for Biotechnology Information (NCBI) was used to search for the genome sequence of the monkeypox virus, and the potential G4 structure in the monkeypox genome was analyzed using the QGRS-mapper website and G4Hunter software. The analysis process is as follows: Figure 2 As shown in A; preliminary analysis of potential G4 sequences by GC% and QGRS G4 score, the results are as follows Figure 2 As shown in B, two potential G4-forming sequences were found; the NCBI database was then used to analyze the sequence conservation in different monkeypox virus strains, and the G4H score of PGQs was used to evaluate the G4-forming ability. The results are shown in Figure 2 C, a highly conserved G4 potential forming sequence 39kDa virion core protein G3 (as shown in SEQ ID No. 2) was found, which was named MG, and the 39kDa virion core protein G1 and G3 in the orthopoxvirus were analyzed for conservation. The results are as follows Figure 2 D, indicating that it is highly conserved.
[0047] In this example, in order to prove that only MG sequences rich in base G can form a G4 structure, the base G in the MG sequence was mutated to base U to obtain a mutant of MG, which was named MG-mut (as shown in SEQ ID No. 3). In this example, the G4 formation ability of the above MG and MG-mut was tested by measuring the gel migration rate. The results are shown in FIG. Figure 3 As shown in A, the above MG has a faster mobility than the corresponding mutant MG-mut, proving that MG folds into a compact secondary structure.
[0048] N-methylmesoporphyrin IX (NMM) is a well-known fluorescent G4-specific ligand that can be used to study the in vitro formation of G4. In this example, NMM was used to perform fluorescence detection on the above-mentioned MG. The results are as follows: Figure 3 As shown in B, it can be seen that MG can enhance the fluorescence effect of NMM.
[0049] In this example, one-dimensional nuclear magnetic resonance (NMR) was used to characterize the above-mentioned MG and its mutant MG-Mut. 1 HNMR spectrum detection, the results are as follows Figure 3 As shown in Figure C, the NMR results show that MG has an obvious peak in the characteristic chemical shift region of G4s (10.2-12.5 ppm), which further proves that MG can fold into the G4 structure.
[0050] In this example, 10 mM Tris, 100 mM K + The above MG and its mutant MG-Mut were subjected to CD spectroscopy in a buffer solution of pH=7.2. The results are as follows Figure 3 As shown in D, the CD spectrum of MG shows a typical positive molar ellipsometric peak at 262 nm and a negative molar ellipsometric peak at 240 nm, while the mutant MG-Mut does not, further indicating that MG can form a parallel G4 structure.
[0051] In this example, a G4-specific antibody BG4 commonly used in the art was used to perform immunofluorescence co-localization detection in 293t cells. The results are as follows: Figure 3 As shown in E, the FAM-labeled MG sequence was found to colocalize with BG4, indicating that MG G4s can be formed in cells.
[0052] In summary, the nucleotide sequence found in the present invention, such as the highly conserved G4 potential forming sequence 39kDa virion core protein G3 (MG) shown in SEQ ID No. 2, can fold into a stable G4 structure in vitro and in cells.
[0053] Example 3: Use of MH3-Λ in the treatment or prevention of diseases caused by monkeypox virus infection
[0054] 1. Verification of interaction force
[0055] The gene encoding the MG core protein of the monkeypox virus in Example 2 is A5L as shown in the nucleotide sequence of SEQ ID No. 1. The mRNA encoding the gene A5L of the monkeypox virus has a parallel rG4 (RNA G-quadruplex) structure, which has different structural strengths with different compound enantiomers. Therefore, this example is for the chiral metal supramolecular compound [Fe2L3] obtained in Example 1 4+ The Λ enantiomer (MH3-Λ) and the chiral metal supramolecular compound [Fe2L3] 4+ The interaction / binding ability of the Δ enantiomer (MH3-Δ) with MG G4s in A5L mRNA rG4 was verified.
[0056] In this example, the effects of MH3-Λ and MH3-Δ on the thermal stability of the MG G4 structure were detected by drawing fluorescence dissolution curves. Figure 4 As shown in A, it can be seen that MH3-Λ significantly enhances the thermal stability of the MG G4 structure compared to MH3-Δ. The binding constant of MH3-Λ and MG G4 structure was measured by UV titration. The results are shown in Figure 4 B, its binding constant is 1.22×10 6 , indicating that there is a strong interaction between MG and MH3-Λ.
[0057] 2. Verification of regulated translation
[0058] Given that mRNA G4s are involved in regulating translation-related processes, it is speculated that G4 in the A5L mRNA promoter may be involved in regulating the translation process of A5L mRNA. To verify the above speculation, this example constructed an enhanced green fluorescent protein (EGFP) reporter gene system to explore the effect of MG on translation described in Example 2.
[0059] Construction of EGFP reporter vector: Using pLV-EGFP-N as the backbone gene reporter vector (Inovogen Tech. Co., Beijing, China), the above-mentioned MG (nucleotide sequence as shown in SEQ ID No. 2), MG-Mut (nucleotide sequence as shown in SEQ ID No. 3) and A5L (nucleotide sequence as shown in SEQ ID No. 1) gene sequences were cloned and inserted into the pLV-EGFP vector through the two restriction sites of EcoRI and BamHI, respectively, to obtain MG-WT-EGFP, MG-WT-EGFP and A5L-EGFP reporter vectors (as shown in Figure 5 and Figure 8 shown).
[0060] In this example, the MG-WT-EGFP and MG-WT-EGFP reporter vectors obtained above were transfected into HEK293T cells, and the effects of MH3-Λ and MH3-Δ on the expression of MG-WT-EGFP protein were analyzed by Western blotting analysis and confocal fluorescence experiments.
[0061] like Figure 6 As shown, both MH3-Λ and MH3-Δ increased the expression of MG-WT-EGFP protein. Figure 7 As shown, MH3-Λ and MH3-Δ had no significant effect on the expression of MG-Mut-EGFP protein, indicating that the MH3-Λ and MH3-Δ metal helical compounds prepared in Example 1 enhanced the expression of MG protein by targeting the G4 structure. Moreover, the above results all indicate that MH3-Λ has a higher ability to induce protein expression than MH3-Δ, further indicating that there is a strong interaction between MG and MH3-Λ.
[0062] In this example, the A5L-EGFP reporter vector obtained above was transfected into HEK293T cells, and the enhancer and promoter regions of A5L-EGFP mRNA and the reporter plasmid were analyzed. The results showed that no other G4-forming motifs were found. The results of Western blotting analysis and confocal fluorescence experiment analysis showed that Fig. 9 As shown, both the MH3-Λ and MH3-Δ metal helical compounds prepared in Example 1 can upregulate the expression of A5L-EGFP fusion protein, indicating that the formation of MG G4 structure promotes the expression of monkeypox core protein encoded by A5L gene.
[0063] In order to further illustrate the regulatory mechanism of MG G4 on A5L gene encoding monkeypox core protein, the stability of EGFP mRNA was detected in pMG-WT-EGFP transfected cells added with MH3-Λ. Fig.10As shown, it can be seen that the addition of MH3-Λ significantly enhanced the stability of EGFP mRNA in pMG-WT-EGFP transfected cells.
[0064] The gene encoding the monkeypox virus MG core protein in Example 2 is the A5L gene as shown in the nucleotide sequence of SEQ ID No. 1, and the mRNA of the A5L gene has a parallel rG4 (RNA G-quadruplex) structure, and its interaction strength with different enantiomers of the compound is different; according to the above experimental results, it can be proved that the monkeypox virus encoding gene A5L mRNArG4 and [Fe2L3] 4+ The Λ enantiomer (MH3-Λ) has stronger binding ability with [Fe2L3] 4+ The binding of the Δ enantiomer (MH3-Δ) was relatively weak. After MH3-Λ bound to A5L mRNA rG4, it effectively enhanced the stability of A5L mRNA and the expression of 39k Da core protein (MG). It can be seen that MH3-Λ can simultaneously enhance the immune response caused by monkeypox virus, reduce the production of monkeypox virus, and prevent the further spread of monkeypox virus.
[0065] Effect experiment:
[0066] The viral core protein with a molecular weight of 39 kDa is encoded by the A5L gene and is a highly conserved immunogenic protein in poxviruses. It plays a vital role in activating host immune responses and promoting the conversion of intracellular virions (IV) to intracellular mature virions (IMV).
[0067] This example verifies whether MH3-Λ obtained in Example 1 can exert its anti-monkeypox virus effect by specifically targeting the G4 structure inside the virus.
[0068] In this example, the cytotoxicity of MH3-Λ in Vero cells was evaluated by CCK8 detection. Fig.11 As shown, the concentration of MH3-Λ that causes 50% cytotoxicity (CC 50 ) was 10.27 μM. Monkeypox virus (MPXV) was used to conduct antiviral experiments with different concentrations of MH3-Λ, and quantitative analysis was performed using image-J. The anti-monkeypox virus effect of MH3-Λ was evaluated by qPCR. The qPCR evaluation primer sequences are shown in SEQ ID No.4, SEQ ID No.5 and SEQ ID No.6. The results are shown in Fig.12 As shown, after adding 5 μM MH3-Λ to Vero cells infected with MPXV, the viral infection activity (PFU) of MPXV and the F3L-specific viral nucleic acid copy number decreased in a dose-dependent manner, indicating that MH3-Λ has a potential antiviral effect on MPXV.
[0069] In this example, GAPDH was used as the internal reference gene (the internal reference gene primer sequences are shown in SEQ ID No. 7 and SEQ ID No. 8), and the expression levels of IL-6, IL-10, IL-α, IL-1β and IL-12 in Vero cells infected with monkeypox virus after adding a safe concentration of 5 μM MH3-Λ were detected by mRNA relative expression levels. The results are shown in Fig.13 As shown, the primer sequences for detecting the expression level of IL-6 are shown in SEQ ID No.9 and SEQ ID No.10, the primer sequences for detecting the expression level of IL-10 are shown in SEQ ID No.11 and SEQ ID No.12, the primer sequences for detecting the expression level of IL-α are shown in SEQ ID No.13 and SEQ ID No.14, the primer sequences for detecting the expression level of IL-1β are shown in SEQ ID No.15 and SEQ ID No.16, and the primer sequences for detecting the expression level of IL-12 are shown in SEQ ID No.17 and SEQ ID No.18.
[0070] It can be seen that the addition of MH3-Λ enhanced the expression of IL-6, IL-10, IL-α, IL-1β and IL-12 during monkeypox virus infection, indicating that it enhanced the immune response to MPXV and further enhanced the inhibition of the virus (e.g. Fig.14 shown).
[0071] The contents not described in detail in the specification of the present invention are well-known technologies for those skilled in the art. Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be based on the definition of the claims.
Claims
1. Use of a chiral metal supramolecular compound in the preparation of an anti-monkeypox drug, characterized in that: The chiral metal supramolecular compound is [Fe2L3] 4+ The Λ enantiomer of .
2. The use according to claim 1, characterized in that: The chiral metal supramolecular compound is composed of two Fe 2+ It combines with three ligands through coordination bonds to form a hexacoordinated right-handed binuclear metal triple-helical cylindrical structure.
3. The use according to claim 2, characterized in that: The structural formula of the ligand is:
4. The use according to claim 1, characterized in that: The chiral metal supramolecular compound binds to the mRNA G4 structure of the A5L gene, and the A5L gene encodes the 39kDa core protein of the monkeypox virus.
5. The use according to claim 4, characterized in that: The mRNA nucleotide sequence of the A5L gene is shown in SEQ ID No.
1.
6. The use according to claim 1, characterized in that: The effective added safety concentration of the chiral metal supramolecular compound in Vero cells is 10.27 μM.
7. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a chiral metal supramolecular compound and a pharmaceutically acceptable carrier, wherein the chiral metal supramolecular compound is [Fe2L3] 4+ The Λ enantiomer of .
8. Use of the pharmaceutical composition according to claim 7 in the preparation of anti-monkeypox drugs.
Citation Information
Patent Citations
Metallic supermolecule compound for inhibiting telomere enzymatic activity, using method and uses thereof
CN101270078A
Application of chiral metal supramolecular compound in preparing anti-tumor stem cell medicines
CN107375298A
Twisted lanthanide metal europium supramolecular cage complex, preparation method and application
CN115850260A
Application of metal supramolecular compound in preparation of medicine for resisting new coronavirus
CN117815397A
